Indometacin farnesil
Nonsteroidal anti-inflammatory prodrug
Pharmaceutical compound
Indometacin farnesil (INN) is a prodrug of the nonsteroidal anti-inflammatory drug (NSAID) indometacin,[1] designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan[2] and Indonesia, under the trade names Infree and Dialon, respectively.
References
- ^ Hirohata S, Yanagida T, Kawai M, Kikuchi H (November 1999). "Inhibition of human B cell activation by a novel nonsteroidal anti-inflammatory drug, indometacin famesil". Immunopharmacology. 44 (3): 245–254. doi:10.1016/S0162-3109(99)00084-3. PMID 10598881.
- ^ "Infree (indometacin farnesil capsules) Full Prescribing Information" (PDF). Eisai Co., Ltd. Archived from the original (PDF) on 2010-12-03. from Eisai Co.
pyrazolones / pyrazolidines | |
---|---|
salicylates | |
acetic acid derivatives and related substances | |
oxicams | |
propionic acid derivatives (profens) |
|
n-arylanthranilic acids (fenamates) | |
COX-2 inhibitors (coxibs) | |
other | |
NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |